

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Michael Sheppard · Marcello D. Bronstein · Pamela Freda · Omar Serri ·
Laura De Marinis · Luciana Naves · Liudmila Rozhinskaya · Karina Hermosillo Reséndiz ·
Matthieu Ruffin · YinMiao Chen · Annamaria Colao

Published online: 8 January 2015
© Springer Science+Business Media New York 2015

Erratum to: Pituitary
DOI 10.1007/s11102-014-0585-6

An error appears twice in the published article: in the first row, second column of Tables 4 and 5. Both columns were labelled: Extension baseline. The authors would like to note that this text is incorrect; both column labels have been corrected to: Core baseline.

The online version of the original article can be found under doi:[10.1007/s11102-014-0585-6](https://doi.org/10.1007/s11102-014-0585-6).

M. Sheppard (✉)
Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
e-mail: m.c.sheppard@bham.ac.uk

M. D. Bronstein
Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of São Paulo Medical School, São Paulo, Brazil

P. Freda
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA

O. Serri
Service of Endocrinology, Centre Hospitalier de l'Université de Montréal, Notre-Dame Hospital, University of Montreal, Montreal, Canada

L. De Marinis
Section of Endocrinology, Department of Internal Medicine, Università Cattolica del Sacro Cuore, Rome, Italy

L. Naves
Unit of Endocrinology, Department of Internal Medicine, University of Brasilia, Brasilia, Brazil

L. Rozhinskaya
Endocrinology Research Center, Moscow, Russia

K. Hermosillo Reséndiz
Clinical Development, Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA

M. Ruffin
Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland

Y. Chen
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

A. Colao
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, Naples, Italy

Table 4 Overall shift in glucose from core baseline to last available value up to month 26

	Core baseline n (%)	Last reported value			
		<100 mg/dL n (%)	100 to <126 mg/dL n (%)	≥126 mg/dL n (%)	Missing n (%)
Pasireotide LAR (N = 178)					
<100 mg/dL	119 (66.9)	35 (19.7)	60 (33.7)	23 (12.9)	1 (0.6)
100 to <126 mg/dL	51 (28.7)	10 (5.6)	18 (10.1)	23 (12.9)	0
≥126 mg/dL	7 (3.9)	0	3 (1.7)	4 (2.2)	0
Missing	1 (0.6)	1 (0.6)	0	0	0
Total	178 (100.0)	46 (25.8)	81 (45.5)	50 (28.1)	1 (0.6)
Octreotide LAR (N = 180)					
<100 mg/dL	109 (60.6)	66 (36.7)	40 (22.2)	3 (1.7)	0
100 to <126 mg/dL	54 (30.0)	17 (9.4)	30 (16.7)	7 (3.9)	0
≥126 mg/dL	17 (9.4)	2 (1.1)	7 (3.9)	8 (4.4)	0
Missing	0	0	0	0	0
Total	180 (100)	85 (47.2)	77 (42.8)	18 (10.0)	0

Shaded boxes represent the patients with a shift in glucose level (mg/dL) that indicates a worse diabetic status at the last reported value compared with core baseline

Table 5 Overall shift in HbA_{1c} from core baseline to last available value up to month 26

	Core baseline n (%)	Last reported value				Missing n (%)
		<5.7 % n (%)	5.7 to <6.5 % n (%)	6.5 to <8 % n (%)	≥8 % n (%)	
Pasireotide LAR (N = 178)						
<5.7 %	74 (41.6)	17 (9.6)	39 (21.9)	13 (7.3)	4 (2.2)	1 (0.6)
5.7 to <6.5 %	87 (48.9)	4 (2.2)	35 (19.7)	42 (23.6)	6 (3.4)	0
6.5 to <8 %	17 (9.6)	1 (0.6)	2 (1.1)	9 (5.1)	5 (2.8)	0
≥8 %	0	0	0	0	0	0
Missing	0	0	0	0	0	0
Total	178 (100.0)	22 (12.4)	76 (42.7)	64 (36.0)	15 (8.4)	1 (0.6)
Octreotide LAR (N = 180)						
<5.7 %	66 (36.7)	31 (17.2)	32 (17.8)	2 (1.1)	0	1 (0.6)
5.7 to <6.5 %	82 (45.6)	7 (3.9)	57 (31.7)	15 (8.3)	2 (1.1)	1 (0.6)
6.5 to <8 %	30 (16.7)	1 (0.6)	13 (7.2)	12 (6.7)	3 (1.7)	1 (0.6)
≥8 %	2 (1.1)	0	0	1 (0.6)	1 (0.6)	0
Missing	0	0	0	0	0	0
Total	180 (100)	39 (21.7)	102 (56.7)	30 (16.7)	6 (3.3)	3 (1.7)

Shaded boxes represent the patients with a shift in HbA_{1c} level (%) that indicates a worse diabetic status at the last reported value compared with core baseline